Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 2—February 2008

Letter

Increasing Resistance in Commensal Escherichia coli, Bolivia and Peru

Alessandro Bartoloni*Comments to Author , Lucia Pallecchi†, Costanza Fiorelli*, Tiziana Di Maggio†, Connie Fernandez‡, Ana Liz Villagran§, Antonia Mantella*, Filippo Bartalesi*, Marianne Strohmeyer*, Angela Bechini*, Herlan Gamboa§, Hugo Rodriguez‡, Charlotte Kristiansson¶, Göran Kronvall¶, Eduardo Gotuzzo#, Franco Paradisi*, and Gian Maria Rossolini†
Author affiliations: *Università di Firenze, Florence, Italy; †Università di Siena, Siena, Italy; ‡Hospital Apoyo Yurimaguas, Yurimaguas-Loreto, Peru; §Servicio Departamental de Salud Santa Cruz, Camiri, Bolivia; ¶Karolinska Institute, Stockholm, Sweden; #Universidad Peruana Cayetano Heredia, Lima, Peru;

Main Article

Table

Antimicrobial drug–resistance rates of Escherichia coli as part of 
commensal flora in children, Bolivia and Peru, 2002 and 2005*
*Expanded Table available online at www.cdc.gov/EID/content/14/2/338-T.htm.

Drug† 2002 2005 p value‡
AMP 95 96 <0.05
CRO 0.1 1.7 <0.001
TET 93 93 NS
SXT 94 94 NS
CHL 70 69 NS
STR 82 92 <0.001
KAN 28 29 <0.05
GEN 21 27 <0.001
AMK 0.4 0.1 NA
NAL 35 57 <0.001
CIP 18 33 <0.001

Prevalence expressed as percentages. In 2002, n = 3,174, mean age 34.8 mo; in 2005, n = 3,193, mean age 33.7 mo (mean age p<0.05).
†AMP, ampicillin; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, chloramphenicol; STR, streptomycin; KAN, kanamycin; GEN, gentamicin; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin.
‡Wald test applied to establish the statistical significance of parameters obtained from logistic regression analysis; NS, not significant; NA, not applicable (due to lack of variability of data).

Main Article

TOP